Partners taking aim at DED in American veterans
September 16, 2021
TearLab, MellingMedical reach an agreement to enhance early detection of dry eye disease in veterans.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Dry Eye Awareness
Researchers pioneer technology that leads successful clinical trial to treat dry eye disease
October 04, 2021
A team of investigators at the Texas Tech University Health Sciences Center have developed a technology derived from corneal epithelial stem cells to improve outcomes for DED patients.
Alcon kicks off year-long partnership with Complexity Gaming
August 23, 2021
According to the company, its partnership will educate the gaming community on common dry eye symptoms and introduce over-the-counter options like its Systane brand of eye drops.
Novaliq completes enrollment in second Phase 3 study of candidate to treat dry eye
August 10, 2021
The company is evaluating topical cyclosporine to treat the signs and symptoms of dry eye disease.
Treatment Options for Dry Eye Flares
July 27, 2021
Cynthia Matossian, MD, FACS, discusses the short- and long-term treatment options for dry eye flares.
Seeking Out Medical Care for Dry Eye Flares
July 20, 2021
Dr Matossian explains the importance of treating dry eye flares and what can happen if they are left unchecked.
Awareness of Dry Eye Flares
July 13, 2021
Dr Matossian elaborates on how both patients’ and physicians’ awareness of dry eyes flares affects their eyesight and how they move forward with treatment.
Dry Eye Flares: An Overview
June 30, 2021
Cynthia Matossian, MD, FACS, provides an overview on dry eye flares, including causes, symptoms, and her experience with dry eye flare patients.
Smartphone screening and referral increases access to care for people with eye problems
June 22, 2021
According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.
Oyster Point Pharma enrolls first subject in phase 2 clinical trial of OC-01 nasal spray for neurotrophic keratopathy
June 21, 2021
Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).